The latest announcement is out from XORTX Therapeutics Inc ( (TSE:XRTX)). On December 31, 2025, XORTX Therapeutics highlighted newly published, independent genome-wide research showing more than 400 ...
Remedy Entertainment has announced Control: Resonant, the follow-up to IGN’s 2019 Game of the Year, Control, at the 2025 Game Awards. It’s due out in 2026 for PC, PS5, and Xbox Series X and S, and it ...
The 2019 game Control is basically the SCP Foundation mixed with Twin Peaks and X-Men, kinda. It takes place entirely within a brutalist building called “The Oldest House,” with impossible geometry ...
Remedy Entertainment's long-awaited sequel to 2019's Control is almost here. On Thursday at The Game Awards, the developer revealed Control Resonant, a sequel to the first game that will make major ...
The game picks up as Dylan’s former captors, the Federal Bureau of Control (FBC), are deploying him at the peak of a supernatural crisis to combat a mysterious cosmic entity. Per the official logline, ...
It’s called Control Resonant, and it brings the supernatural threat to Manhattan. It’s called Control Resonant, and it brings the supernatural threat to Manhattan. is an entertainment editor covering ...
You can always count on Remedy to defy expectations, and it's certainly doing that with Control Resonant. When you purchase through links on our site, we may earn an affiliate commission. Here’s how ...
Cruise control is available in most new vehicles. Adaptive Cruise Control adjusts your speed based on how close you are to other vehicles. Driving on the freeway for long distances can get a bit ...
CALGARY, Alberta, Oct. 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (XRTX) (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company ...
Control: Ultimate Edition will be available on the iPhone, the iPad and the Apple Vision Pro in early 2026, its developer Remedy has announced. The developer says you can either "tap into the action ...
Nicolas Forsans does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...